Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity
This article was originally published in PharmAsia News
Executive Summary
Questions during an April 28 court hearing suggest Mylan Pharmaceuticals Inc. may have a difficult time persuading a federal judge that it has standing, at this time, to force an FDA determination on generic marketing exclusivity rights for Pfizer's Lipitor